| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Cash and cash equivalents at beginning of period | 1,443 | - |
| Net loss | -28,982 | -23,092 |
| Depreciation and amortization expense | 28 | - |
| Amortization of operating right of use assets | 15 | - |
| Stock-based compensation | 147 | 79 |
| Common stock issued in exchange for services | 600 | 150 |
| Change in fair value of warrant liabilities | 8,481 | 3,518 |
| Change in fair value of convertible promissory notes | 8,032 | - |
| Loss on convertible note conversions | -4,239 | -3,467 |
| Gain on exercise of warrant liabilities | 5,369 | - |
| Loss on issuance of registered direct common stock | -730 | -729 |
| Loss on consideration shares and warrants | -1,277 | -1,277 |
| Change in fair value of convertible note payable | - | 6,530 |
| Expense for debt issuance costs due to fair value election on anson notes | 350 | 350 |
| Warrant issuance costs related to alvogen termination | 0 | 0 |
| Convertible note default penalty | 0 | 0 |
| Prepaid expense and other assets | -414 | -187 |
| Account receivable | -12 | - |
| Depreciation expense | - | 0 |
| Accounts payable | 100 | -501 |
| Insurance loan payable | 0 | 0 |
| Operating lease liabilities | -63 | - |
| Accrued expense and other liabilities | -412 | -202 |
| Net cash used in operating activities | -10,399 | -7,508 |
| Business acquisition, net of cash acquired | 2,561 | - |
| Net cash used in investing activities | -2,561 | - |
| Repayment of convertible note | 0 | 0 |
| Repayment of insurance note | 394 | 394 |
| Expense for debt issuance costs due to fair value election on anson notes | 350 | 350 |
| Proceeds from issuance of insurance loan | 227 | 452 |
| Proceeds from anson convertible note, net | 5,000 | 5,000 |
| Proceeds from liability classified warrants | 0 | - |
| Atm offering, net of offering costs | 4,751 | 1,012 |
| Proceeds from issuance of common stock and warrants, net of issuance costs-Consideration Warrants | 9,468 | 3,255 |
| Proceeds from issuance of common stock and warrants, net of issuance costs-Warrants Other Than Consideration Warrants | 0 | 0 |
| Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 18,701 | 8,975 |
| Net increase (decrease) in cash and cash equivalents | 5,741 | 1,467 |
| Cash and cash equivalents at end of period | 7,200 | - |
NRX Pharmaceuticals, Inc. (NRXPW)
NRX Pharmaceuticals, Inc. (NRXPW)